San Francisco, CA – September 22, 2025 – VeriSIM Life, a leading innovator in AI-driven drug development and translational intelligence, is proud to announce that it has been shortlisted as a finalist in the prestigious 2025 Scrip Awards, under the Innovation Award category.
San Francisco, CA – September 22, 2025 – VeriSIM Life, a leading innovator in AI-driven drug development and translational intelligence, is proud to announce that it has been shortlisted as a finalist in the prestigious 2025 Scrip Awards, under the Innovation Award category.
San Francisco, CA – September 8, 2025 – VeriSIM Life, a leading AI-first biotechnology company, today announced it has been named a finalist for the prestigious AI in Action award category in the 2025 Reuters Pharma Awards. This award recognizes organizations and individuals who have demonstrably worked to reduce patient burden, amplify patient communities, and advance the patient voice in pharmaceutical research and development.
San Francisco, CA – September 8, 2025 – VeriSIM Life, a leading AI-first biotechnology company, today announced it has been named a finalist for the prestigious AI in Action award category in the 2025 Reuters Pharma Awards. This award recognizes organizations and individuals who have demonstrably worked to reduce patient burden, amplify patient communities, and advance the patient voice in pharmaceutical research and development.
San Francisco, CA — VeriSIM Life, with its leading AI-driven biosimulation platform transforming drug development, is proud to announce that its Founder and CEO, Dr. Jo Varshney, has been honored with the 2025 International Women Entrepreneur Award in IT by Great Companies.
San Francisco, CA — VeriSIM Life, with its leading AI-driven biosimulation platform transforming drug development, is proud to announce that its Founder and CEO, Dr. Jo Varshney, has been honored with the 2025 International Women Entrepreneur Award in IT by Great Companies.
.png)
.png)
AtlasGEN Novel Drug Designer efficiently identifies new molecules based on favorable chemical properties and simultaneously evaluates them for clinical safety and effectiveness based on biology using VeriSIM Life’s groundbreaking Translational Index™ technology.
Iterative ranking of target engaging hits by their Translational Index values reduces the time and cost associated with other computational hit discovery approaches, while compressing the hit-to-lead refinement and optimization process by pre-validating hits for translatability. This unique integration dramatically reduces the number of compounds to evaluate in subsequent experimental research.
The ability to generate target engaging compound hits depends largely on the size of the molecular search library. The AtlasGEN search space is supported by more than 1 trillion compounds. Generative AI and deep learning techniques deliver unprecedented discovery capability.
AtlasGEN accurately predicts protein-lygand binding affinity by combining geometric conformer analysis with machine learning based on experimental data 72% more efficiently than molecular docking-based approaches.
.png)
